^
    Back
    Association details:
    Biomarker:AHNAK2 mutation + TP53 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Front Oncol
    Title:

    Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

    Published date:
    03/10/2022
    Excerpt:
    ...we compared ICI response between patients with TP53 mutation only and patients with both TP53 and AHNAK2 mutation. As shown in Figure 2D, patients with AHNAK2 and TP53 co-mutations achieved a higher ORR than patients with TP53 mutation only.
    DOI:
    https://doi.org/10.3389/fonc.2022.798401